The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: A comparison of meta-analyses

European Journal of Epidemiology

Volumn 19, Issue 4, 2004, Pages 353-363

  Melegaro, Alessia ^a,b,d   Edmunds, W John ^a,c  

^a HPA Communic Dis Survlnc Centre   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c CITY UNIVERSITY   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Elderly; High risk; Meta analysis; Polysaccharide pneumococcal vaccine (PPV); Vaccine efficacy (VE)

Indexed keywords

PNEUMOCOCCUS VACCINE; 23 VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE;

AGE DISTRIBUTION; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; INFECTION RISK; LOBAR PNEUMONIA; META ANALYSIS; POPULATION RISK; REVIEW; RISK ASSESSMENT; STREPTOCOCCUS INFECTION; TREATMENT OUTCOME; VACCINATION; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK;

AGED; CONFIDENCE INTERVALS; HUMANS; ODDS RATIO; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT;

EID: 3242889227     PISSN: 03932990     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:EJEP.0000024701.94769.98     Document Type: Review

References (36)

1. CDC. Prevention of pneumococcal disease: Recommendations of the advisory committee on immunisation practices (ACIP). MMWR 1997; 46(RR-08): 1-24.
2. Obaro SK, Monteil MA, Henderson DC. Fortnightly review: The pneumococcal problem. Br Med J 1996; 312: 1521.
3. Ortqvist A. Pneumococcal vaccination: Current and future issues. Eur Resp J 2001; 18: 184-195.
4. Salisbury DM, Begg NT. Immunisation against infectious disease, Bicentenary Edition. London: HMSO, 1996.
5. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA et al. Efficacy of pneumococcal vaccination in adults - A meta analysis of randomized controlled trials. Arch Intern Med 1994; 154: 2666-2677.
6. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000; 1.
7. Hutchinson BG, Oxman AD, Shannon HS, Lioyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine - Meta-analysis. Can Family Physician 1999; 45: 2381-2393.
8. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: A meta-analysis of randomized trials. Vaccine 2001; 19: 4780-4790.
9. Rubins JB, Alter M, Loch J, Janoff EN. Determination of antibody responses of elderly adults to all 23 capsular polysaccharide after pneumococcal vaccination. Infect Immun 1999; 67: 5979-5984.
10. Leinonen M, Syrjala H, Jalonen E, Kujala P, Herva E. Demonstration of pneumolysin antibodies in circulating immune complexes - a new diagnostic method for pneumococcal pneumonia. Serodiag Immunother Inf Dis 1990; 4: 451-458.
11. Jadad A. Assessing the quality of reports of RCTs: Is blinding necessary? Control Clin Trials 1996; 17: 1-12.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
13. Johan Giesecke. Modern Infectious Disease Epidemiology. London: Edward Arnold, 1994.
14. Oxman AD, Cook DJ, Guyatt GH. Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group. JAMA 1994; 272: 1367-1371.
15. Kaufman P. Pneumonia in old age. Active immunisation against pneumonia with pneumococcus polysaccharide. Results of a six year study. Arch Intern Med 1947; 518-531.
16. Gaillat J, Zmirou D, Mallaret MR, Rouhan D, Bru JP, Stahl JP et al. Essai clinique du vaccin antipneumococcique chez des personnes agees vivant en institution. Rev Epidem Sante Publ 1985; 33: 437-444.
17. Honkanen P, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among elderly persons aged 65 years or older. Vaccine 1999; 17: 2493-2500.
18. Klastersky J, Mommen P, Cantraine F, Safary A. Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma. Eur J Cancer Clin Oncol 1986; 22: 807-813.
19. Koivula I, Sten M, Leinonen M, Makela H. Clinical efficacy of pneumococcal vaccine in the elderly: A randomized, single-blind population-based trial. Am J Med 1997; 103: 281-290.
20. Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vacination Study Group. Lancet 1998; 351(9100): 399-403.
21. Davis AL, Aranda CP, Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease - a pilot study. Chest 1987; 92: 204-212.
22. Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL. Efficacy of pneumococcal vaccine in high-risk patients - results of a veterans administration cooperative study. N Engl J Med 1986; 315: 1318-1327.
23. Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ 1987; 136: 361-365.
24. Riley ID, Andrews M, Howard R, Tarr PI, Pfeiffer M, Challands P. Immunisation with a polyvalent pneumococcal vaccine. Lancet 1977; 1338-1341.
25. Smit P, Oberholzer D, Hayden-Smith S. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977; 238: 2613-2616.
26. Austrian R, Douglas RM, Schiffman G. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physician 1976; 89: 184-194.
27. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of penumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984; 101: 325-330.
28. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1453-1460.
29. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108: 653-657.
30. Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995; 155: 2336-2340.
31. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommandations. JAMA 1993; 270: 1826-1831.
32. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in high-risk population. Am J Med 1987; 83: 425-430.
33. Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WF 3rd. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986; 104: 1-6.
34. Sisk JE, Moskowitz AJ, Whang W, Lin JD, Fedson DS, McBean AM et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278: 1333-1339.
35. Ament A, Baltussen R, Duru G, Rigaud-Bully C, de Graeve D, Ortqvist A et al. Cost-effectiveness of pneumococcal vaccination of older people: A study in 5 European countries. Clin Inf Dis 2000; 31: 444-450.
36. Claxton K, Neumann PJ, Araki S, Weinstein M. Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease. Intern J Technol Assess Health Care 2001; 17: 38-55.